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Regulated exocytosis is subject to several modulatory steps that include phosphorylation events and transient protein–
protein interactions. The estrogen receptor-binding fragment-associated gene9 (EBAG9) gene product was recently
identified as a modulator of tumor-associated O-linked glycan expression in nonneuronal cells; however, this molecule is
expressed physiologically in essentially all mammalian tissues. Particular interest has developed toward this molecule
because in some human tumor entities high expression levels correlated with clinical prognosis. To gain insight into the
cellular function of EBAG9, we scored for interaction partners by using the yeast two-hybrid system. Here, we demon-
strate that EBAG9 interacts with Snapin, which is likely to be a modulator of Synaptotagmin-associated regulated
exocytosis. Strengthening of this interaction inhibited regulated secretion of neuropeptide Y from PC12 cells, whereas
evoked neurotransmitter release from hippocampal neurons remained unaltered. Mechanistically, EBAG9 decreased
phosphorylation of Snapin; subsequently, association of Snapin with synaptosome-associated protein of 25 kDa
(SNAP25) and SNAP23 was diminished. We suggest that the occurrence of SNAP23, Snapin, and EBAG9 also in
nonneuronal cells might extend the modulatory role of EBAG9 to a broad range of secretory cells. The conjunction
between EBAG9 and Snapin adds an additional layer of control on exocytosis processes; in addition, mechanistic evidence
is provided that inhibition of phosphorylation has a regulatory function in exocytosis.
INTRODUCTION
The secretion of biomolecules in many types of eukaryotic
cells is mediated through both the constitutive and regu-
lated transport of vesicles (Burgess and Kelly, 1987).
Whereas constitutive exocytosis involves a continuous flow
and fusion of vesicles between cellular organelles and to the
plasma membrane, regulated exocytosis is characterized by
vesicle trafficking, followed by vesicle fusion with the target
membrane only in the presence of elevated levels of cyto-
plasmic Ca2 (Burgoyne and Morgan, 2003). The best stud-
ied variant of regulated exocytosis includes the synaptic
transmission in neuronal and neuroendocrine cells, where
upon arrival of Ca2 trigger neurotransmitter release from
preformed vesicles is effectuated (Chen et al., 1999; Jahn and
Su¨dhof, 1999; Rettig and Neher, 2002).
Consent has emerged that vesicle fusion with a target
membrane is a stepwise process that involves several pro-
tein families, including soluble N-ethylmaleimide-sensitive
factor attachment protein receptors (SNAREs), Rab proteins,
and Sec1/Munc-18–related molecules (Jahn and Su¨dhof,
1999). The synaptic vesicle cycle starts with the tethering and
docking of vesicles in the active zones of the plasma mem-
brane, followed by a priming step that includes the forma-
tion of a SNARE complex (Su¨dhof, 1995; Fernandez-Chacon
and Su¨dhof, 1999). SNAREs are a superfamily of small and
mostly membrane-anchored proteins that share a common
motif of 60 amino acids. A functional neuronal SNARE
complex in cells is formed between SNARE proteins resid-
ing in vesicle membranes, including vesicle-associated
membrane protein (VAMP), and the plasma membrane with
the t-SNARE proteins Syntaxin and synaptosome-associated
protein of 25 kDa (SNAP25) (So¨llner et al., 1993; Sutton et al.,
1998).
The candidate Ca2 sensor Synaptotagmin I is localized to
synaptic vesicles and large dense-core vesicles (LDCVs)
(Brose et al., 1992; Geppert et al., 1994). Synaptotagmin I acts
at a postdocking step in exocytosis, including a maturation
step of primed vesicles into the readily releasable pool (RRP)
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of vesicles (Voets et al., 2001), but also a final fusion-pore
opening stage (Wang et al., 2001; Chapman, 2002). Recently,
a novel SNAP25-interacting protein, Snapin, was identified.
It was suggested that cAMP-dependent protein kinase A
(PKA)-mediated phosphorylation of Snapin enhanced bind-
ing to SNAP25. This interaction improved the binding affin-
ity of Synaptotagmin I to SNAP25 and the SNARE complex
in vitro. By using a phosphomimetic mutant of Snapin, not
only an increase in size of the exocytotic burst but also an
enhanced sustained component of exocytosis in chromaffin
cells was seen (Ilardi et al., 1999; Chheda et al., 2001). In
support of a more general role in intracellular membrane
fusion events, additional Snapin-interacting proteins were
identified that are not limited to neuronal transmitter re-
lease, among them novel subunits of the biogenesis of lyso-
some-related organelles complex-1 (BLOC-1) and adenylyl
cyclase VI (Chou et al., 2004; Starcevic and Dell’Angelica,
2004).
In this study, we refer to our previous report on estrogen
receptor-binding fragment-associated gene9 (EBAG9), also
termed receptor-binding cancer antigen expressed on SiSo
cells (RCAS1), which caused the occurrence of tumor-asso-
ciated O-linked glycans on cell lines that are normally neg-
ative for these antigens. EBAG9 is an estrogen-inducible,
ubiquitously expressed protein with close homologues in
human and murine rodents that exhibits a Golgi-predomi-
nant localization in nonneuronal cells (Tsuchiya et al., 2001;
Engelsberg et al., 2003). This raised the question of what
function EBAG9 under physiological conditions has and
whether this function relates to its proposed tumor associa-
tion (Ikeda et al., 2000; Kubokawa et al., 2001; Suzuki et al.,
2001; Tsuneizumi et al., 2001; Leelawat et al., 2003; Akahira et
al., 2004). Using full-length EBAG9 as the bait to screen a
human brain cDNA library, we identified Snapin as an
interaction partner of EBAG9 and verified the relevance of
this interaction in exocytosis assays. Overexpression of
EBAG9 inhibited regulated secretion of neuropeptide Y
(NPY) in intact PC12 cells, whereas constitutive secretion of
1-antitrypsin in HepG2 cells remained unaffected. In con-
trast, EBAG9 overexpression in hippocampal neurons did
not alter synaptic transmission. Mechanistically, EBAG9 in-
hibited Snapin phosphorylation, which subsequently atten-
uated Snapin binding to SNAP25 and SNAP23. These data
demonstrate that EBAG9 is a novel modulator of regulated
exocytosis that acts upstream of Snapin and the SNARE
complex.
MATERIALS AND METHODS
Cell Culture and Transfections
Human embryonic kidney (HEK)293 and HepG2 cells were cultured in
DMEM medium (PAA Laboratories, Co¨lbe, Germany), supplemented with
10% fetal calf serum (Biochrom, Berlin, Germany), 2 mM l-glutamine, and 100
U/ml penicillin-streptomycin. PC12 cells were grown with additional 10%
horse serum (Invitrogen, Carlsbad, CA). HEK293 cells were transfected by
electroporation by using a Bio-Rad gene pulser. PC12 cells were transfected
by using LipofectAMINE 2000 (Invitrogen).
Antibodies
A polyclonal rabbit anti-EBAG9 serum was described previously (Engelsberg
et al., 2003). Monoclonal antibodies (mAbs) against Synaptophysin and
VAMP2 were obtained from Synaptic Systems (Go¨ttingen, Germany); mAbs
against EEA1, GM130, and p115 were from BD Biosciences (San Jose, CA);
and anti-FLAG mAbs M2 and M5 were from Sigma Chemie (Deisenhofen,
Germany). Biotinylated anti-green fluorescent protein (GFP) antibody was
purchased from Vector Laboratories (Burlingame, CA), goat anti-1-antitryp-
sin antibody was from U.S. Biochemical (Cleveland, OH), and goat anti-
glutathione S-transferase (GST) antibody was from Amersham Biosciences
(Freiburg, Germany). A rabbit anti-GFP serum was used for immunoprecipi-
tation (a kind gift of R. Schu¨lein, Forschungsinstitut fu¨r Molekulare Pharma-
kologie, Berlin, Germany), and a rabbit anti-Snapin serum was kindly pro-
vided by R. Jahn (Max-Planck-Institut fu¨r Biophysikalische Chemie,
Go¨ttingen, Germany) (Vites et al., 2004).
Expression Plasmid Constructs
Deletion variants or site-directed mutants of EBAG9 (Engelsberg et al., 2003)
and Snapin were constructed by polymerase chain reaction (PCR) by using
sequence specific primer pairs (see Supplementary Information S1). Full-
length Snapin cDNA was isolated in a yeast two-hybrid screen from a human
brain cDNA library (kindly provided by H.-J. Scha¨ffer, Max-Delbru¨ck-Center
for Molecular Medicine, Berlin, Germany). GST-SNAP23 was generated by
PCR by using SNAP23-pcB7 (Koticha et al., 1999) as template. All constructs
were verified by cDNA sequencing.
Generation of Recombinant Fusion Proteins, In Vitro
Transcription, and Translation
The expression of GST and His6-fusion proteins in Escherichia coli DH5 was
done essentially as described previously (Smith and Johnson, 1988). Briefly,
fusion protein constructs were cloned into pGEX-4T-1 (Amersham Bio-
sciences, Piscataway, NJ) or pQE-32, respectively (QIAGEN, Hilden, Ger-
many), followed by induction with 1 mM isopropyl -d-thiogalactoside.
Bacterial pellets were sonicated and lysed in phosphate-buffered saline (PBS)/
0.5% Triton X-100 (TX-100). GST or polyhistidine-tagged fusion proteins were
purified by binding to glutathione-Sepharose (Amersham Biosciences) beads
or nickel-nitrilotriacetic acid agarose (QIAGEN), respectively. Quantification
of recovered fusion protein was done by Bradford protein assay and by
SDS-PAGE and Coomassie Brilliant Blue staining. In vitro transcription and
translation were performed in the presence of [35S]methionine/cysteine (Ex-
press protein labeling mix; PerkinElmer Life and Analytical Sciences, Boston,
MA), according to the manufacturer’s instructions by using Promega Ribo-
probe kit (Promega, Madison, WI) and the Promega Flexi rabbit reticulocyte
system.
Yeast Two-Hybrid Screen
A full-length human EBAG9 cDNA was inserted in-frame into pGBKT7 bait
vector (BD Biosciences Clontech, Palo Alto, CA) containing the GAL4 DNA-
binding domain (BD). Expression was confirmed by SDS-PAGE and immu-
noblotting. Yeast cells (AH109) were sequentially transformed with pGBKT7-
EBAG9 bait vector and a human brain cDNA library in the GAL4 activation
domain (AD) containing vector pACT2 (BD Biosciences Clontech) according
to the protocols described for the MATCHMAKER GAL4 two-hybrid system
3 (BD Biosciences Clontech). Transformants were selected on plates lacking
tryptophan, leucine, histidine, and adenine and supplemented with 5-bromo-
4-chloro-3-indolyl--d-galactopyranoside (Glycosynth). Prey plasmids from
Ade, His, Mel1 clones were rescued and confirmed by retransformation
into fresh yeast cells with the pGBKT7-EBAG9 bait or various control baits.
-Galactosidase (lacZ) activity was quantified by liquid culture assay by using
standard protocols. The prey plasmids were subjected to DNA sequencing
and analyzed by BLAST search.
In Vitro Binding Assays
In vitro-translated 35S-labeled EBAG9 was incubated with 3 g of the indi-
cated GST fusion protein immobilized on glutathione-Sepharose in NP-40
binding buffer (50 mM Tris, pH 7.4, 5 mM MgCl2, 0.5% NP-40, 1 mM
phenylmethylsulfonyl fluoride, and 1.5 g/ml aprotinin). After incubation
for 3 h at 4°C, beads were washed extensively in binding buffer, and bound
protein was released by boiling in Laemmli reducing sample buffer. An
aliquot of the sample was analyzed by 12.5% SDS-PAGE and bound 35S-
labeled EBAG9 was visualized by autoradiography. The remaining sample
was separated by SDS-PAGE and stained with Coomassie Brilliant Blue to
control equal load of various GST fusion proteins. Usually, this binding assay
was done under saturating conditions.
In a competitive binding assay, 10 g of immobilized GST-SNAP25 or
GST-mSNAP23 was incubated with a constant amount of in vitro-translated
35S-labeled Snapin and increasing amounts of 35S-labeled EBAG9. Beads were
washed extensively with 50 mM Tris, pH 7.4, 50 mM NaCl, and 0.5% TX-100,
and bound protein was analyzed by SDS-PAGE.
For pulldown assays, transiently transfected HEK293 cells were lysed in
binding buffer (25 mM HEPES, pH 7.4, 140 mM KCl, 20 mM NaCl, and 0.5%
CHAPS). Three hundred micrograms of cell lysate was incubated with 4.5 g
of the indicated GST fusion protein immobilized on glutathione-Sepharose
beads in binding buffer (0.3% CHAPS). Beads were washed in binding buffer,
resuspended in sample buffer, and separated using SDS-PAGE. Bound
EBAG9-GFP was visualized with biotinylated anti-GFP antibody. For binding
assays with Snapin-GFP, transfected HEK293 cells were lysed in binding
buffer (50 mM Tris, pH 7.4, 50 mM NaCl, and 0.5% TX-100). Cell lysates were
incubated with the indicated GST fusion proteins in binding buffer containing
0.1% TX-100. Beads were processed as described above.
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Coimmunoprecipitation, Gel Electrophoresis, and
Immunoblotting
Cell extracts were prepared from cotransfected HEK293 cells by using TX-100
containing lysis buffer (50 mM Tris, pH 7.4, 50 mM NaCl, and 0.5% TX-100).
Solubilized proteins were incubated with 5 g of anti-FLAG mAb M5 or
rabbit anti-GFP serum and protein A-Sepharose (Amersham Biosciences) in
binding buffer (50 mM Tris, pH 7.4, 50 mM NaCl, 0.1% bovine serum albumin,
and 0.1% TX-100). Beads were washed three times with binding buffer and
bound proteins were separated on a 12.5% SDS-PAGE, followed by transfer to
nitrocellulose membranes. Blots were further processed as described above,
by using primary antibodies as detailed in the figure legends (Rehm and
Ploegh, 1997).
The ratio between total recombinant Snapin-GFP and FLAG-tagged EBAG9
in cell lysates in relation to their amount found in a complex with their
respective binding partner was assessed by densitometric scanning of bands
obtained from immunoblotting by using identical antibodies. Usually, 1/40
volume of the cell lysate was used to assess total cellular content of the fusion
proteins.
Laser Scanning Microscopy
HEK293 cells were cotransfected with Snapin-GFP and pcDNA-EBAG9 and
grown on coated coverslips for 36 h, essentially as described previously
(Engelsberg et al., 2003). Bound antibodies were detected with a biotinylated
secondary antibody (Southern Biotechnology Associates, Birmingham, AL)
and streptavidin-conjugated Alexa Fluor 568 (Molecular Probes, Eugene, OR).
Confocal images were acquired with a confocal laser scanning microscope
LSM510 (Carl Zeiss, Jena, Germany). Fluorescence signals were detected
using the following configurations: GFP exc 488 nm, BP em 500–530 nm,
Alexa Fluor 568 exc  543 nm, and LP em  560 nm). Acquisition was
performed using a multi track to prevent bleed-through. All images were
processed using LSM Examiner or LSM Browser software.
For confocal microscopic analysis of PC12 cells, cells were grown on colla-
gen-coated coverslips. Where indicated, PC12 cells were stimulated for 3 d
with nerve growth factor (-NGF, 150 ng/ml; Sigma Chemie). Zeiss LSM510
software was used for quantification of fluorescence intensities along repre-
sentative lines through intracellular regions and through neurite extensions.
Gel Filtration and Subcellular Fractionation
PC12 cells were solubilized in lysis buffer (50 mM Tris-HCl, pH 7.4, 50 mM
NaCl, 1 mM MgCl2, 0.5% CHAPS, and protease inhibitors), and precleared
cell lysate was applied to a Superdex 200 16/60 column (Amersham Bio-
sciences), preequilibrated with elution buffer (50 mM Tris-HCl, pH 7.4, 50 mM
NaCl, and 0.2% CHAPS) at a flow rate of 0.3 ml/min. Fractions (1.5 ml) were
precipitated with trichloroacetic acid (TCA) and analyzed by immunoblot-
ting. For the assessment of void volume (V0), the column was calibrated with
blue dextran (2000 kDa) and for the determination of molecular weight the
protein standards ferritin (440 kDa), aldolase (158 kDa), ovalbumin (43 kDa),
and ribonuclease A (14 kDa) were used.
For subcellular fractionation experiments, PC12 cells were stimulated for
3 d with -NGF (150 ng/ml), and cell homogenization and fractionation on a
discontinuous sucrose gradient was performed exactly as described (Rehm
and Ploegh, 1997). Briefly, a postnuclear supernatant was adjusted to 40%
(wt/vol) sucrose in a buffer containing 10 mM Tris-HCl, pH 7.4, and layered
on a 50% sucrose solution. Subsequently, a discontinuous sucrose gradient
consisting of 35, 25, 15, and 0% (wt/vol) was poured on top of the 40% sucrose
fraction. The gradient was centrifuged for 16 h at 170,000  g (SW41 rotor).
Fractions were harvested (0.75 ml) from the top and analyzed by immuno-
blotting.
Generation of Adenovirus Vectors and Transduction of
Cell Lines
EBAG9 was subcloned in the expression cassette of pQBI-AdCMV5-GFP
(Qbiogene, Illkirch, France), followed by homologous recombination with a
viral backbone vector in HEK293A cells. Ad-EBAG9-GFP and Ad-GFP were
expanded, purified, and titered as described previously (Cichon et al., 1999).
Generation of Semliki Forest Virus
Wild-type EBAG9 was cloned into the Semliki Forest Virus expression vector
(based on pSFV1; Invitrogen) containing the respective EBAG9 cDNA se-
quence fused to enhanced green fluorescent protein (eGFP) (Ashery et al.,
1999).
NPY Release Assay
NPY-T7-GST secretion assay in PC12 cells was essentially performed as
described previously (Fukuda, 2003). Briefly, PC12 cells (6-cm dish) were
cotransfected with pShooter-NPY-T7-GST and EBAG9-GFP, EBAG9-GFP
C12/14/27S or GFP (mock). Three days after transfection, cells were stimu-
lated with either high KCl buffer (56 mM KCl, 95 mM NaCl, 2.2 mM CaCl2, 0.5
mM MgCl2, 5.6 mM glucose, and 15 mM HEPES, pH 7.4) or low KCl buffer
(5.6 mM KCl, 145 mM NaCl, 2.2 mM CaCl2, 5.6 mM glucose, 0.5 mM MgCl2,
and 15 mM HEPES, pH 7.4) for 10 min at 37°C. Released NPY-T7-GST was
recovered by incubation with glutathione-Sepharose beads. After extensively
washing with NP-40 lysis buffer (0.5% NP-40, 50 mM Tris, pH 7.4, and 5 mM
MgCl2) proteins bound to the beads were analyzed by 12.5% SDS-PAGE
followed by immunoblotting with anti-GST antibody. The intensity of the
immunoreactive bands on x-ray film was quantified by computer analysis
(Tina 2.0; Raytest, Pittsburgh, PA).
Metabolic Labeling and 1-Antitrypsin Secretion
HepG2 cells were infected with Ad-EBAG9-GFP or Ad-GFP at the multiplic-
ity of infection (MOI) indicated in the figure legend. Cells were starved,
metabolically labeled with 250 Ci of [35S]methionine/cysteine for 10 min,
and chased essentially as described previously (Rehm and Ploegh, 1997).
After the chase, cells were washed in PBS and lysed in NP-40 buffer (see
above). 1-Antitrypsin was immunoprecipitated from precleared cell lysates
and from culture supernatant with anti-1-antitrypsin antibody immobilized
on protein A-Sepharose. Bound protein was analyzed by SDS-PAGE and
autoradiography. Protein levels were quantified by densitometric scanning.
For palmitoylation, HEK293 cells were transiently transfected with EBAG9-
GFP, GFP, or EBAG9-mutants. Twenty-four hours after transfection, cells
were incubated in serum-free medium for 16 h, followed by labeling with
[3H]palmitic acid (400 Ci/ml) for 4 h. GFP or GFP-tagged proteins were
recovered from NP-40 lysates with anti-GFP serum. Immunoprecipitates were
analyzed on SDS-PAGE under nonreducing conditions. Gels were fixed with
10% methanol/10% acetic acid for 90 min before autoradiography. In some
experiments, [3H]palmitate-labeled immunoprecipitates were split, and ali-
quots were run on separate lanes on SDS-PAGE. After fixation, gels were cut
and identical immunoprecipitates were subjected to either 1 M Tris-HCl, pH
7.4, or 1 M hydroxylamine-HCl, pH 7.4, treatment before autoradiography.
Phosphorylation Experiments
Snapin-GFP was cotransfected with an equal amount of pcDNA-EBAG9 or
empty vector (mock). Cells were starved for 1 h in phosphate-free DMEM
(MP Biomedicals, Irvine, CA), followed by metabolic labeling with 500 Ci of
[32P]orthophosphoric acid (MP Biomedicals) for 1 h in phosphate-free DMEM.
Cells were then stimulated with 30 ng/ml phorbol 12-myristate 13-acetate
(PMA), 40 M forskolin, or remained unstimulated for 10 min at 37°C.
Phosphorylated cells were washed and lysed in radioimmunoprecipitation
buffer (50 mM Tris, pH 7.5, 50 mM NaCl, 0.5% NP-40, 0.25% deoxycholate, 0.5
mM EDTA, 1 mM Na3VO4, 10 mM NaF, and protease inhibitors) for 1 h at
4°C. Snapin was immunoprecipitated with rabbit anti-GFP serum, immuno-
precipitates were resolved by SDS-PAGE, and Snapin was visualized by
autoradiography. Snapin phosphorylation levels were quantified and normal-
ized for Snapin protein loads, as assessed by immunoblotting. In vitro phos-
phorylation experiments were performed essentially as described previously
(Chheda et al., 2001), by using 1 U/l catalytic subunit PKA (Promega) or
casein kinase II (CKII) (PerkinElmer Life and Analytical Sciences). Phosphor-
ylation levels were quantified by phosphorscreen and normalized to equimo-
lar protein amounts, as determined by Coomassie Brilliant Blue staining.
Electrophysiological Analysis of Cultured Hippocampal
Neurons
Microisland cultures of mouse hippocampal neurons were prepared from
NMRI mice and maintained as described previously (Reim et al., 2001).
Neurons were grown in a chemically defined medium (NBAB27; Invitro-
gen) and infected with Semliki Forest Virus after 10–14 d in vitro. For each
experiment, approximately equal numbers of infected and uninfected control
cells from the same preparation were measured in parallel and blindly 8–10
h after infection. Recording conditions (21°C), data acquisition, and analysis
were performed as described previously (Rosenmund and Stevens, 1996;
Reim et al., 2001).
RESULTS
EBAG9 Recruits the SNARE-associated Protein Snapin
To assess the physiological role of the EBAG9-encoded gene
product, we scored for intracellular interaction partners by
using a yeast two-hybrid screen. Full-length human EBAG9
was used as a bait for screening of a human brain cDNA
library. Approximately 106 independent clones were
screened for activation of the reporter genes Ade, His, and
Mel1/lacZ, and nine interacting clones were readily ob-
tained. Strongest induction of the -galactosidase reporter
was observed for two clones, both contained full-length
cDNAs encoding Snapin (Figure 1A). Specificity of the
EBAG9–Snapin association was shown by transformations
of control bait and prey plasmids (Figure 1B).
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To confirm a selective interaction between EBAG9 and
Snapin, in vitro binding assays using recombinant fusion
proteins were performed. Because GST-EBAG9 is synthe-
sized at extremely low rate in bacteria and is not soluble in
aqueous solutions (Engelsberg et al., 2003), EBAG9 was
translated in vitro and incubated with GST-Snapin. Whereas
35S-labeled EBAG9 associated with GST-Snapin exclusively,
the GST-tagged SNARE proteins SNAP25, VAMP2, and GST
alone failed to recover EBAG9 in this in vitro pulldown
assay (Figure 2A). In vitro-translated major histocompatibil-
ity complex (MHC) class I heavy chain HLA-A3 failed to
interact with GST-Snapin, which argued against a nonspe-
cific adsorption of Snapin (Supplementary Information S2).
EBAG9 Binds to Snapin In Vivo
The interaction between EBAG9 and Snapin was further
confirmed by association of in vitro-translated EBAG9 with
GST-Snapin and by coimmunoprecipitation assays from
transfected HEK293 cells. Although various epitope-tagged
Snapin eukaryotic expression plasmids were generated, only
a polyclonal anti-GFP antibody was suitable to immunopre-
cipitate GFP-tagged Snapin. A specific binding of properly
folded Snapin to the GST-fusion proteins SNAP25 and
SNAP23 was revealed (Figure 2B). The ubiquitously ex-
pressed SNAP25 homologue SNAP29 failed to interact with
Snapin-GFP.
Coimmunoprecipitation of Snapin-GFP and N-FLAG-
EBAG9 in cotransfected HEK293 cells was seen by using the
anti-FLAG antibody M5 (Figure 2C). Reciprocal coimmuno-
precipitation yielded the same results (Figure 2D). Bound
Snapin accounted for 4% of recombinant Snapin expressed
in the starting material, as determined by densitometric
scanning of bands obtained in total lysate and after coim-
munoprecipitation. Conversely, the determination of recom-
binant FLAG-tagged EBAG9 associated with Snapin yielded
an amount of 12% related to the total cell lysate. These
rates could reflect transient interactions and relate to the
number of fully assembled SNARE complexes in neuronal
cells, which is in the range of 4–5% (Matveeva et al., 2003).
To further support our observation that EBAG9 and
Snapin proteins are associated in vivo, we subjected a PC12
cell extract to size exclusion chromatography on a Sephadex
200 column. The majority of both EBAG9 and Snapin eluted
at a molecular weight larger than 440 kDa with a significant
cofractionation in fractions 9–15 (Figure 2E). This fraction-
ation profile of Snapin is consistent with a recent publication
showing the cofractionation of Snapin with the BLOC-1 in
fractions corresponding to 600 kDa (Starcevic and
Dell’Angelica, 2004). Only a minor proportion of Snapin
(fraction 43) and EBAG9 (fractions 33–35) eluted at positions
corresponding to the expected monomers. In addition, we
observed the occurrence of Snapin also in fractions 27–29
(molecular weight range 66–98 kDa) where EBAG9 was
essentially absent. This points to the potential presence of
other association partners; alternatively, multimeric Snapin
complexes might occur.
Identification of the Binding Domains Relevant for
EBAG9–Snapin Association
To map the binding regions relevant for EBAG9–Snapin
Interaction, binding assays of EBAG9-GFP with GST-Snapin
or truncated fusion proteins were performed. Analysis of the
human Snapin-cDNA sequence applying the Coils program
algorithm (Lupas et al., 1991) predicted two helical regions
(H1, aa 37–65 and H2, aa 83–126). The C-terminal coiled-coil
domain (H2) was characterized as a binding domain for
SNAP25 and SNAP23 (Ilardi et al., 1999; Buxton et al., 2003).
In contrast, the N-terminal hydrophobic domain (HD; aa
1–20) was suggested to be involved in membrane association
of Snapin (Ilardi et al., 1999). Two GST-Snapin deletion
mutants, 1–20 and 83–136, were analyzed for their bind-
ing to full-length EBAG9-GFP. The predicted N-terminal
-helix domain (H1) of Snapin was sufficient to confer bind-
ing to EBAG9, whereas a deletion of the predicted hydro-
phobic domain (1–20) or the deletion of the C-terminal
coiled-coil domain (83–136) was dispensable for the ob-
served association (Figure 3A). This observation argued
against an aspecific interaction due to clustered basic resi-
dues in the C terminus of Snapin.
To define the region of EBAG9 involved in binding
Snapin, binding analysis of EBAG9-GFP wild-type (wt) and
truncated fusion proteins with GST-Snapin were performed.
Full-length EBAG9 and all other mutants exhibited similar
binding efficiency, whereas the N-terminal truncated vari-
ant, EBAG9-GFP 1–27, with a deletion of the putative
transmembrane (TM) and intraluminal extreme N terminus,
was essentially negative. A deletion mutant that exhibited
the predicted transmembrane and intraluminal short N
Figure 1. Yeast two-hybrid studies of
EBAG9 interacting clones. (A) Screening of a
human brain cDNA library allowed the iden-
tification of nine EBAG9-interacting clones.
Clones 7 and 6B showed strongest lacZ re-
porter activation and encoded full-length
Snapin. The positive control is represented by
a clone consisting of BD-p53 and AD-SV40
T-antigen. The combination BD-EBAG9 and
AD-SV40 T-antigen provided the negative
control (0%). -Galactosidase activity is ex-
pressed as percentage of the positive con-
trol. Data represent the mean values  SD
of three independent transformants. (B)
Specificity of EBAG9 –Snapin association.
Yeast cells were cotransformed with the in-
dicated GAL4 DNA BD and GAL4 AD plas-
mids. The unrelated bait BD-Lamin C rep-
resented an additional negative control.
Colonies were screened for interaction by
their ability to grow in the absence of histidine and adenine and by -galactosidase activity (Mel1). , no interaction; , strong
interaction.
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terminus only, EBAG9-GFP 30–213, was sufficient to con-
fer binding to a GST-Snapin fragment containing the first
coiled-coil domain (aa 21–82) (Figure 3B).
These data suggested that the association between EBAG9
and Snapin was mediated by the N-terminal domain of
EBAG9 and the N-terminal coiled-coil domain (H1) of
Snapin.
Membrane Association and Posttranslational
Modifications of EBAG9 and Snapin
Our previous study did not rule out the possibility that the
predicted TM-domain (aa 8–27), which contains three cys-
teine residues, was palmitoylated and thus provides a lipid
anchor for a peripheral membrane association of EBAG9
(Engelsberg et al., 2003). To revisit this observation, the
subcellular localization of the EBAG9 cysteine mutant C12/
14/27S was analyzed. The mutant exhibited a dispersed
cytoplasmic staining pattern; in contrast, EBAG9 wt local-
ized to the Golgi region (Figure 4A). Palmitoylation of
EBAG9 was assessed in [3H]palmitic acid labeled and tran-
siently transfected HEK293 cells. EBAG9 was immunopre-
cipitated from detergent lysates, and a specific band for wt
EBAG9, but not for the cysteine mutant or the truncated
mutant (1–27) lacking the palmitoylation acceptor sites on
SDS-PAGE was obtained (Figure 4B). As expected for a
thioester linkage, the palmitate label was removed by treat-
ment with neutral hydroxylamine (Figure 4C). The cytoplas-
mic staining pattern of the mutant implies that the subcellular
localization of EBAG9 is dependent on the palmitoylation an-
chor, which would allow greater accessibility for the interac-
tion with Snapin.
To explore membrane association and co- or posttransla-
tional modifications, Snapin was translated in vitro in re-
ticulocyte lysate. The cotranslational addition of microsomes
did not result in a size shift in SDS-PAGE (Figure 5A).
Therefore, a potential N-glycosylation site (N110) was not
used. To probe for a posttranslational membrane association
of Snapin, in vitro translation of Snapin was stopped by the
inclusion of cycloheximide, and microsomes were added.
Microsomal membrane-bound Snapin was analyzed by
SDS-PAGE, demonstrating a posttranslational association of
Snapin, possibly recruited through protein–protein interac-
tions (Figure 5B).
Figure 2. EBAG9 interacts with Snapin in vitro
and in vivo. (A) GST-Snapin, GST-SNAP25, GST-
VAMP2, or GST (3 g each) immobilized on gluta-
thione-Sepharose beads were incubated with in
vitro-translated 35S-labeled EBAG9. Bound proteins
were analyzed by 12.5% SDS-PAGE and autora-
diography (top). An aliquot was separated by SDS-
PAGE and stained with Coomassie Blue to control
equal load of various GST fusion proteins (bottom,
Input GST). To score for the amount of in vitro-
translated EBAG9 (Input EBAG9), one-quarter of
the translation mix was resolved by SDS-PAGE
(top). (B) HEK293 cells were transiently transfected
with Snapin-GFP, solubilized in TX-100–contain-
ing lysis buffer, and cell lysate was then incubated
with immobilized GST-fusion proteins, as indi-
cated. Bound proteins were resolved by SDS-PAGE
and transferred to nitrocellulose. Immunodetection
of Snapin-GFP (IB) was done with biotinylated an-
ti-GFP antibody (top). After stripping, the same
membranes were probed with anti-GST antibody to
confirm comparable loading of GST-fusion proteins
(bottom). (C) HEK293 cells were transfected with
Snapin-GFP, N-FLAG-EBAG9, or both. Cells were
lysed in TX-100–containing lysis buffer and immu-
noprecipitations (IPs) were carried out with anti-
FLAG mAb M5. Immunoprecipitates were ana-
lyzed by SDS-PAGE, followed by immunoblotting
with biotinylated anti-GFP antibody (top). An ali-
quot (1/40) of the cell lysate was assessed for the
expression of recombinant EBAG9 (middle), by us-
ing a polyclonal anti-EBAG9 serum for IB. Bottom,
the amount of Snapin-GFP in the starting material
was determined using an anti-GFP antibody. (D)
Cell lysates of HEK293 cells transfected with
EBAG9-C-FLAG, Snapin-GFP or both were pro-
cessed as shown in C and immunoprecipitated with
rabbit anti-GFP serum. Coimmunoprecipitated
EBAG9-C-FLAG was detected in IB with anti-
FLAG mAb M2 (top). Snapin-GFP was detected
with biotinylated anti-GFP antibody (bottom, Input
Snapin); the middle panel shows EBAG9-C-FLAG
expressed in cell lysates. (E) Size exclusion chroma-
tography. PC12 cells were lysed in CHAPS-contain-
ing lysis buffer, followed by separation on a Super-
dex 200 gel filtration column as described under Materials and Methods. Fractions were analyzed by SDS-PAGE and immunoblotting for
EBAG9 and Snapin. The positions of molecular weight standards and Vo are indicated.
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Snapin localizes to the cytosol of nonneuronal cells, but it
also was found on perinuclear membranes and at the plasma
membrane itself (Buxton et al., 2003). When HEK293 cells
were cotransfected with Snapin-GFP and pcDNA-EBAG9,
Snapin was found in the cytosol (green), but perinuclear
staining was obtained as well (Figure 5C). In this region,
signals for EBAG9 and Snapin were overlapping (merge,
yellow), indicating an association of both molecules at the
Golgi complex.
Subcellular Localization of EBAG9 in Neuroendocrine
Cells
Snapin is a SNARE-associated protein involved in regulated
secretion; therefore, we explored the intracellular distribu-
tion of EBAG9 in PC12 cells that are equipped with an
abundant regulated exocytosis machinery. In undifferenti-
ated PC12 (NGF) cells, EBAG9-GFP was predominantly
localized to the perinuclear region (Figure 6A). In contrast,
in NGF-stimulated PC12 cells (NGF) EBAG9-GFP revealed
an additional punctate staining pattern, with enrichments in
the neurite extensions and at the cell periphery.
Neurite extensions in PC12 cells are enriched for LDCV
and synaptic-like vesicles (Chilcote et al., 1995). The identity
of EBAG9-positive vesicular structures in NGF-stimulated
PC12 cells was explored by double immunofluorescence
staining with the secretory vesicle marker molecules Synap-
tophysin (Figure 6A) and VAMP2 (Figure 6B). Comparison
of EBAG9-GFP with Synaptophysin or VAMP2 revealed a
significant overlap in neurite extensions of differentiated
PC12 cells (NGF) (merge, yellow), whereas in undifferen-
tiated cells (NGF) the staining pattern is clearly separate
(shown for Synaptophysin). Analysis of fluorescence inten-
sities along a line in two representative areas showed a high
degree of overlap, indicating sites with high concentrations
of EBAG9 and VAMP2 (Figure 6C).
To score for colocalization with organelle-specific markers
in NGF-treated PC12 cells, a subcellular fractionation was
performed (Figure 7, A and B). Postnuclear supernatant
prepared from PC12 cells was fractionated by equilibrium
centrifugation on a discontinuous sucrose gradient. Gradi-
ent fractions were analyzed for marker proteins by immu-
noblotting.
We observed significant overlap of EBAG9 with the secre-
tory vesicle marker proteins VAMP2 and Synaptophysin in
the lower buoyant density region of the gradient, but also a
significant cofractionation with the Golgi marker proteins
p115 and GM130.
We conclude that EBAG9 is subject to a dynamic redistri-
bution in differentiated neuroendocrine cells, as supported
by a flexible lipid membrane anchor (see above).
EBAG9 Inhibits Regulated Exocytosis
Subcellular localization in NGF-stimulated PC12 cells and
association with the SNARE-associated molecule Snapin
suggested a modulatory role for EBAG9 in regulated exocy-
tosis. By using an established neurosecretion assay in tran-
Figure 3. Mapping of the interaction
sites between EBAG9 and Snapin. (A)
Snapin associates with EBAG9 via its
predicted N-terminal coiled-coil do-
main. Lysates of EBAG9-GFP–trans-
fected HEK293 cells were incubated
with the indicated GST-Snapin dele-
tion mutants or the Snapin S50D mu-
tant. Complexes were washed in
CHAPS-containing lysis buffer and
bound EBAG9-GFP was analyzed by
SDS-PAGE and immunoblotting (IB)
by using biotinylated anti-GFP anti-
body (top). Blots were stripped and
reprobed with anti-GST antibody to
ensure equivalent loading of GST pro-
teins (bottom). Input EBAG9-GFP,
1/40 volume of the reaction mixture
used for each pulldown. On the right,
a schematic representation of GST-
Snapin and its deletion mutants. The
GST tag, the predicted HD and two
predicted coiled-coil domains (H1 and
H2). (B) EBAG9 binds to Snapin via its
predicted TM region. EBAG9 mutants
were expressed and analyzed as
shown in A. The putative transmem-
brane domain alone (EBAG9 30–213-
GFP) was sufficient to associate with
Snapin wt or Snapin aa 21–82, exhib-
iting the H1 domain. Middle, an ali-
quot (1/40 volume) of the cell lysates was
assessed by IB for the expression of equal
amounts of EBAG9-GFP–truncated vari-
ants. Bottom, input GST-Snapin fusion
protein. On the right, a schematic repre-
sentation of EBAG9-GFP and its deletion
mutants. TM, the predicted transmem-
brane region (aa 8–27); CC, coiled-coil do-
main (aa 179–206).
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siently transfected PC12 cells, transient overexpression of
EBAG9 resulted in a statistically significant decrease (mean
46%, p  0.00025) in high K-induced NPY-GST release
(Figure 8A, left), but it had no effect on low K-dependent
secretion (Figure 8A, right). The cysteine-deficient mutant of
EBAG9 (EBAG9 C/S, also referred to as C12/14/27S) failed
to inhibit NPY secretion, indicating that only a membrane-
bound form of the molecule is active in regulated exocytosis.
In addition, the coexpression of Snapin was able to rescue
the inhibition of evoked norepinephrine release from intact
PC12 cells upon EBAG9 overexpression (Supplementary In-
formation S3), suggesting that EBAG9 specifically targets
Snapin. This observation indicated that EBAG9 controls reg-
ulated LDCV exocytosis.
Because EBAG9 and its interaction partner Snapin are
expressed ubiquitously also in nonneuronal cells, we also
addressed the influence of EBAG9 on constitutive exocyto-
sis. When HepG2 cells were infected with adenovirus en-
coding EBAG9 or with a control virus, no differences in
absolute amounts or in the kinetics of 1-antitrypsin secre-
tion were seen (Figure 8B). To further exclude an aspecific
effect of EBAG9 overexpression on the secretory pathway,
we explored the effects of EBAG9 on the endoplasmic
reticulum–Golgi transport of MHC class I molecules and
on the trafficking of cathepsin D from the Golgi complex
to the lysosomal compartment (Supplementary Informa-
tion S4 and S5). In conclusion, we observed no difference
in maturation kinetics of MHC class I molecules or ca-
thepsin D.
Overexpression of EBAG9 Does Not Alter
Neurotransmitter Release in Hippocampal Neurons
The characteristics of synaptic transmission can be reliably
studied in primary cultures. The culture system of choice is
the autaptic microdot culture in which individual neurons
are plated on small astrocyte feeder islands and generate
recurrent or autaptic synapses with themselves. This culture
system has been used successfully in the analysis of a num-
ber of mouse deletion mutants lacking essential presynaptic
proteins, e.g., Synaptotagmin I and Complexin (Geppert et
al., 1994; Reim et al., 2001).
Standard patch-clamp recordings from single isolated
neurons were used to assess possible defects of presynaptic
properties by using a Semliki Forest Virus construct (Ashery
et al., 1999) encoding for EBAG9-GFP. Synaptic responses
were evoked by brief somatic depolarization (2-ms depolar-
ization from 70 mV holding potential to 0 mV) 8–10 h
postinfection and measured as peak inward currents a few
milliseconds after action potential induction (Figure 9A). We
Figure 4. Palmitoylation contributes to membrane association of
EBAG9. (A) HEK293 cells were transiently transfected with wt
EBAG9-GFP (right) or with a cysteine deficient mutant (C12/14/
17S) (left) and were analyzed by confocal microscopy. Bar, 20 m.
(B) HEK293 cells were transfected with EBAG9-GFP, EBAG9 C12/
14/27S-GFP, or EBAG9 1–27-GFP, followed by metabolic labeling
with [3H]palmitic acid for 4 h. Cell lysates were subjected to immu-
noprecipitation with anti-GFP serum (IP) and analyzed by SDS-
PAGE and autoradiography (top). An aliquot (1/5) of the immuno-
precipitates were immunoblotted (IB) with biotinylated anti-GFP
antibody. (C) Aliquots of identical [3H]palmitate-labeled EBAG9-
GFP immunoprecipitates were resolved by SDS-PAGE and treated
separately overnight with 1 M Tris or 1 M hydroxylamine before
autoradiography.
Figure 5. Intracellular distribution of Snapin-GFP. (A) Snapin mRNA was in vitro translated in the presence of [35S]methionine/cysteine
with () or without microsomes (). Translation was stopped by addition of sample buffer and boiling. Total loads were analyzed by
SDS-PAGE and autoradiography. (B) Snapin associates with microsomal membranes co- or posttranslationally. Microsomes were added to
the in vitro translation reaction either at the beginning of translation () or after induction of translation arrest by inclusion of cycloheximide
() (10 g/ml). Microsomes were pelleted, washed twice with PBS, and analyzed as described in text. (C) HEK293 cells were cotransfected
with Snapin-GFP (left, green) and pcDNA-EBAG9. Cells were stained with anti-EBAG9 polyclonal serum (middle). Secondary goat
anti-rabbit antibody and streptavidin-conjugated Alexa Fluor 568 were used to detect staining of the primary polyclonal antibody (red).
Images were analyzed by confocal microscopy; merged images are shown on the right (yellow). Bar, 10 m.
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concentrated our analysis on excitatory glutamatergic neu-
rons, because they are much more abundant than inhibitory
GABAergic cells in autaptic cultures. Excitatory postsynap-
tic current (EPSC) amplitudes recorded from neurons over-
expressing EBAG9 were similar to eGFP expressing cells
(3.0  0.37 nA for control and 3.40  0.65 nA for EBAG9-
overexpressing neurons; p  0.52)
Sizes of RRP were quantified by measuring the responses
of mutant cells and their appropriate controls to application
of 500 mM hypertonic sucrose solution for 4 s. Typically, this
treatment induces release of the RRP, which in turn leads to
a transient inward current followed by a steady current
component (Rosenmund and Stevens, 1996) (Figure 9B). The
transient part consists of a burst-like release of vesicles re-
sulting from the forced fusion of all fusion competent,
primed vesicles. The total number of vesicles in the RRP of
a cell can therefore be quantified by integrating the total
charge of the transient current component after application
of hypertonic solution, divided by the charge of the average
miniature EPSC (mEPSC). As shown in Figure 8B, the
postsynaptic currents measured during application of hy-
pertonic sucrose were not significantly different between
control cells (0.56  0.25 nC) and EBAG9-overexpressing
neurons (0.49  0.08 nC; p  0.36).
When tested at higher stimulation rates, EPSCs from
EBAG9-overexpressing cells and control cells showed simi-
Figure 6. NGF-dependent subcellular redistri-
bution of EBAG9 in PC12 cells. (A) PC12 cells
were transiently transfected with EBAG9-GFP
and cultured in the absence () or presence () of
NGF for 72 h. Cells were fixed, permeabilized,
and then stained with an anti-Synaptophysin or
VAMP2 antibody. Subcellular distribution of
EBAG9-GFP (green) and Synaptophysin or
VAMP2 (red) (B) was analyzed by confocal mi-
croscopy. Merged images are shown on the right.
EBAG9-GFP redistributed from perinuclear re-
gions to vesicular structures and to neurite exten-
sions after NGF treatment. A partial colocaliza-
tion of EBAG9-GFP with the secretory vesicle
markers Synaptophysin and VAMP2 in neurites
of differentiated PC12 cells was obtained (merge,
yellow). Bar, 10 m. (C) Magnification of overlaid
EBAG9-GFP and VAMP2 in neurite extension
and intracellular region. The fluorescence inten-
sities measured along a line show amounts of
EBAG9-GFP and VAMP2. The fluorescence inten-
sities were plotted as number of pixels (y-axis)
relative to their position along the region (x-axis).
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lar degrees of depression (Figure 9C). We conclude that the
effects seen for the EBAG9–Snapin interaction depend on
the regulated exocytosis system, as explored in hippocampal
neurons or in PC12 cells, respectively.
EBAG9 Inhibits the Basal Phosphorylation of Snapin
Snapin has been suggested to be a substrate for the cAMP-
dependent PKA, leading to enhanced association with
SNAP25 and increased exocytosis (Chheda et al., 2001).
Based on our mapping of the interaction domain impor-
tant for EBAG9 binding, which includes the N-terminal
region of Snapin (aa 21–82) and the H1 domain (aa 37–65)
residing therein, we hypothesized that the phosphorylation
of Snapin at residue S50 might be influenced by the associ-
ation with EBAG9.
HEK293 cells were cotransfected with Snapin-GFP and
EBAG9, followed by metabolic labeling with 32Pi and stim-
ulation with the protein kinase C (PKC) inductor PMA or the
PKA inductor forskolin, respectively. Snapin-GFP received a
high basal level of phosphorylation in mock (empty vector)-
transfected cells, whereas the cotransfection of EBAG9 de-
creased the basal phosphorylation of Snapin-GFP signifi-
cantly (mean 50%, p  0.016). Unexpectedly, PKA
stimulation with forskolin failed to increase the basal phos-
phorylation of Snapin (Figure 10A). In our hands, phosphor-
ylation of recombinantly expressed histidine-tagged Snapin
by PKA was even less efficient than those obtained for other
substrates, including SNAP25 and Casein (Figure 10B).
Analysis of the amino acid sequence of Snapin for potential
kinase consensus sites revealed that position S50 can be
targeted by PKA, but this site also was identified as a po-
tential target motif for CKII. In an in vitro phosphorylation
assay, CKII-dependent phosphorylation of Snapin was not
seen. We note that the truncated GST-EBAG9 mutant 1–30
was phosphorylated in abundance by recombinant PKA and
CKII (Figure 10C).
In conclusion, in the presence of EBAG9 in vivo phosphor-
ylation of Snapin is strongly reduced.
EBAG9 Inhibits Binding of Snapin to SNAP25 and
SNAP23
To explore the functional consequences of Snapin associa-
tion with EBAG9, a competition study was carried out using
immobilized GST-SNAP25 and in vitro-translated Snapin.
This system was supplemented with various amounts of in
vitro-translated EBAG9. Increasing amounts of in vitro-
translated EBAG9 gradually impeded association of Snapin
and SNAP25, with a saturation obtained at 25 l of EBAG9
(Figure 11A). Based on the methionine and cysteine content
(Snapin, 3; EBAG9, 7) and relative intensity of both mole-
cules analyzed by densitometric scanning of direct loads
(Huppa and Ploegh, 1997), a 1:1 stoichiometry was sug-
gested for both molecules.
In a similar experimental approach, EBAG9 inhibited
binding of Snapin to SNAP23 (Figure 11B). The modulatory
capacity of EBAG9 in the Snapin–SNAP23 interaction
strongly suggests a more general role for EBAG9 in mem-
brane fusion events in nonneuronal cells as well.
DISCUSSION
The results presented here are of interest for several aspects
of cell biology. First, the identification of Snapin as an inter-
action partner of EBAG9 allowed us to assess the physiolog-
ical function of EBAG9 as a highly conserved and ubiqui-
tously expressed protein in mammalian cells. Second, this
characterization might point to a putative link between high
level expression of EBAG9 in some tumors, exocytosis, and
the occurrence of tumor-associated O-linked glycans (Tsu-
neizumi et al., 2001; Engelsberg et al., 2003; Akahira et al.,
2004). Few examples of plasma membrane glycoproteins
and glycolipids were reported where the Ca2 trigger in
regulated exocytosis also was crucial for the levels of plasma
membrane receptors and transporters, among them the glu-
cose transporter. Surface deposition is regulated in response
to insulin and is mediated by regulated exocytosis (White-
head et al., 2001). We envisage that EBAG9-mediated mod-
ulation of the secretory pathway might favor the deposition
of those truncated, normally cryptic glycans at the cell sur-
face. Other examples that link exocytosis and tumor devel-
opment include the EWS-WT1 gene-fusion product in des-
moplasmic small round cell tumors that gives rise to
overexpression of the Munc13-1–related molecule BAIAP3.
Based on this homology, BAIAP3 was suggested to play a
regulatory role in exocytosis (Palmer et al., 2002).
Snapin itself is implicated in synaptic transmission be-
cause it binds to SNAP25, mediated through its C-terminal
domain (aa 79–136) (Ilardi et al., 1999). Although initially
considered as a brain specific, synaptic vesicle localized
SNARE complex-associated molecule, it has turned out that
Snapin also is expressed in nonneuronal cells. Accordingly,
Snapin also can form a ternary complex with the nonneuro-
nal isoform of SNAP25, SNAP23 (Buxton et al., 2003). Be-
cause we observed a posttranslational membrane associa-
tion in microsomal membranes and a predominant
cytoplasmic staining pattern together with a punctate stain-
Figure 7. EBAG9 cofractionates with secretory vesicle markers. (A)
Postnuclear supernatant (PNS) of NGF-induced PC12 cells was
separated by a discontinuous sucrose density gradient, and frac-
tions were taken from the top. Protein was precipitated with TCA
and analyzed by SDS-PAGE and immunoblotting by using the
antibodies indicated. Fraction 1, top. (B) Protein marker distribution
was quantified by densitometric scanning and expressed as percent-
age of the total amount present in the PNS.
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ing in the perinuclear region of HEK293 cells, we suggest
that Snapin is implicated in vesicle trafficking pathways that
are separate from the specialized forms observed at neuro-
nal synapses. In support of this conclusion, inhibition of
Snapin binding to the nonneuronal SNAP25 homologue
SNAP23 in the presence of EBAG9 suggests a more general
role of EBAG9 and Snapin in membrane fusion events in
other cell types. In addition, the identification of other
Snapin-interacting proteins expanded the role of Snapin to
the biogenesis of lysosome-related organelles and to the
cycling and subcellular localization of adenylyl cyclase VI
through interactions with the SNARE complex, respectively
(Chou et al., 2004; Starcevic and Dell’Angelica, 2004).
The association of EBAG9 with Snapin prompted us to
explore a potential modulatory role of EBAG9 in regulated
exocytosis. The overexpression of membrane-associated
EBAG9 in PC12 cells effectuated a significant reduction in
neuropeptide Y and catecholamine release. A modulatory
impact on regulated exocytosis, but not on constitutive se-
cretion, was suggested by the inability of EBAG9 to alter
1-antitrypsin release from HepG2 cells. These assays sup-
ported our notion that the effects of EBAG9 overexpression
on regulated secretion were specific but not due to a severe
structural or functional disturbance of the secretory path-
way.
The phosphomimetic Snapin mutant S50D increased the
initial exocytotic burst phase, suggesting that Snapin phos-
phorylation positively regulates LDCVs (Chheda et al.,
2001). In contrast, the sustained component of LDCV exocy-
tosis was increased by both mutants, S50D and an S50A
variant, the latter mimics an unphosphorylated state. It was
inferred that Snapin might act additionally as a priming
factor in the presynaptic vesicle cycle (Chheda et al., 2001).
The reduction in release of the surrogate neurotransmitter
NPY upon overexpression of the Snapin inhibitor EBAG9 is
largely in agreement with the suggested function of Snapin
in release from LDCVs. Our failure to observe an inhibitory
effect on evoked neurotransmitter release or size of the RRP
in hippocampal neurons might relate to the lack of concom-
itant overexpression of phosphorylated Snapin as down-
stream effector molecule for EBAG9 (Thakur et al., 2004).
Second, several differences between the release machineries
in chromaffin cells and neurons have been suggested. Chro-
maffin cells release catecholamines from LDCVs, whereas
Figure 8. Membrane-bound EBAG9 inhibits regu-
lated exocytosis in PC12 cells, whereas constitutive
secretion is unaffected. (A) PC12 cells were cotrans-
fected with NPY-GST and EBAG9-GFP, GFP (mock)
or EBAG9 C12/14/27S (C/S). NPY-GST secretion
was stimulated by a 10-min incubation with high KCl
solution (56 mM) or low KCl solution (5.6 mM).
Released NPY-GST was captured with glutathione-
Sepharose beads, and protein bound was analyzed
by SDS-PAGE and immunoblotting. Results are ex-
pressed as percentage of NPY-GST secretion, com-
pared with total cellular NPY-GST. Bars, means SD
of three independent experiments. **p  0.00025,
Student’s unpaired t test. (B) HepG2 cells were in-
fected with Ad-EBAG9-GFP or Ad-GFP (mock) as a
control at MOIs between 5 and 20 for 2 h. After 36 h,
cells were labeled with [35S]methionine/cysteine for
10 min, followed by a chase in complete medium.
After the indicated periods of chase, 1-antitrypsin
was immunoprecipitated and analyzed as detailed in
Materials and Methods. 1-Antitrypsin secreted is ex-
pressed as percentage of total content. Data are
means  SD of a single representative experiment
performed in duplicate. Experiments were per-
formed three times.
Figure 9. Basal parameters of synaptic transmis-
sion, synaptic amplitudes, and readily releasable
vesicle pools. (A) Bar diagram summarizing average
synaptic EPSC amplitudes for EBAG9-GFP
(EBAG9) and eGFP (eGFP)-overexpressing neu-
rons. Data are presented  SEM. Values of n indi-
cate total number of cells. (B) Bar diagram showing
the average size of the charge induced by applica-
tion of 500 mM sucrose during 4 s corresponding to
the RRP. Data and groups are represented as de-
scribed above. (C) Average EPSC amplitude normal-
ized to the first response during application of 50
stimuli at 10 Hz. Data and groups are represented as
described above.
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hippocampal neurons serve as a model system for release
from small clear vesicles. More specifically, differences in
pool sizes and kinetic properties have been recorded (Rettig
and Neher, 2002). Whereas overexpression of priming fac-
tors in chromaffin cells causes large parallel alterations in
pool sizes, those changes have not been observed in neurons
(Betz et al., 2001).
Because Synaptotagmin I affects exclusively the RRP
(Geppert et al., 1994; Voets et al., 2001), the effects of EBAG9
in conjunction with Snapin are unlikely to rest solely on a
reduced binding of Synaptotagmin I to the neuronal SNARE
complex. Instead, Synaptotagmin III and VII were suggested
to play a role during slow/sustained Ca2 triggered exocy-
tosis in PC12 cells, possibly modulated by Snapin and
EBAG9 (Su¨dhof, 2002; Sugita et al., 2002). The effects ob-
served for EBAG9 and Snapin would be in agreement with
a promiscuous role of Snapin where binding of other Syn-
aptotagmin isoforms to the SNARE complex is controlled as
well. In conclusion, we envisage that EBAG9 modulates
priming of Synaptotagmin-associated SNARE complex as-
sembly, as mediated through the linker protein Snapin.
Based on a failure to observe association of Snapin and
SNAP25 in biochemical assays and on lack of effects seen for
overexpression of a C-terminally truncated variant in neu-
ronal transmission, a recent study suggested a reconsidera-
tion of the function of Snapin in neurotransmitter release
Figure 10. EBAG9 inhibits phosphorylation of
Snapin. (A) HEK293 cells were transiently cotrans-
fected with Snapin-GFP and pcDNA-EBAG9 or empty
vector (mock). Cells were labeled with 32Pi and stim-
ulated with 30 ng/ml PMA, 40 M forskolin, or re-
mained unstimulated (none) for 10 min at 37°C.
Snapin-GFP was immunoprecipitated from a deter-
gent lysate with rabbit anti-GFP serum. Immunopre-
cipitates were analyzed by SDS-PAGE and autora-
diography. Snapin-GFP phosphorylation was
quantified using BAS 2000 image analyzer and ex-
pressed as percentage of 32Pi incorporation, compared
with unstimulated, mock-transfected cells (100%).
Snapin-GFP phosphorylation levels were normalized
to protein loads as assessed by immunoblotting (our
unpublished data). Note that neither PMA nor forsko-
lin is able to enhance phosphorylation of Snapin-GFP,
compared with unstimulated cells. Data represent
means  SD of three independent experiments. *p 
0.0156, Student’s unpaired t test. (B) Snapin is an inef-
ficient substrate for recombinant PKA and for CKII
(C). Casein and recombinant proteins GST-SNAP25
(SNAP25), GST-EBAG9 1–30 (EBAG9) and His6-
Snapin (Snapin) (2 g each) were tested for their abil-
ity to receive phosphorylation by 1 U/l PKA or 1
U/l CKII in vitro. Enzymes were preincubated for 10
min at 30°C with 80 M ATP in 25 l of kinase buffer.
Then, 2 Ci of [-32P]ATP was added to the proteins,
and reactions were continued for 30 min at 30°C. Re-
action products were analyzed by SDS-PAGE. Phos-
phorylation levels (Casein, 100%) were quantified by
phosphorscreen and normalized to equimolar protein
amounts, as determined by Coomassie Brilliant Blue
staining. Data represent the mean values SD of three
independent experiments.
Figure 11. EBAG9 prevents association of
Snapin with SNAP25 and SNAP23. (A) A
constant amount of immobilized GST-
SNAP25 (10 g) was incubated with a con-
stant amount of in vitro-translated 35S-la-
beled Snapin. Increasing amounts of 35S-
labeled EBAG9, as obtained from in vitro
translation, were added. Samples were
washed extensively and bound Snapin was
detected by autoradiography. The amount of
Snapin bound to GST-SNAP25 was quanti-
fied and expressed in percentage of Snapin
bound to SNAP25 without inclusion of
EBAG9 (control, 100%). Mock control, reticu-
locyte lysate that lacks EBAG9. (B) Likewise,
inhibition of Snapin binding to GST-SNAP23
(10 g) was determined in the presence of
EBAG9. Data are representative of four inde-
pendent experiments in A and B.
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(Vites et al., 2004). However, in comparison with previous
reports (Ilardi et al., 1999; Chheda et al., 2001; Buxton et al.,
2003) this novel study did not use the S50D mutant or
injection of C-terminal peptides to explore changes in syn-
aptic transmission and is therefore not directly comparable.
Phosphorylation as a regulatory mechanism acts at differ-
ent stages of the vesicle cycle, but only a few substrates with
physiological relevance were identified (Turner et al., 1999;
Evans and Morgan, 2003). Our data on the EBAG9–Snapin
interaction suggest that inhibition of Snapin phosphoryla-
tion might reduce the association of Snapin with SNAP25
and SNAP23, followed by a decrease in Synaptotagmin re-
cruitment. When we revisited the phosphorylation reaction
of Snapin, we failed to observe an enhancement by PMA or
forskolin, which would be expected if PKA or PKC were
involved. However, in contrast to a previous report, we did
not use back-phosphorylation or the cAMP-analogue BIMP
as an inductor of PKA in vivo (Chheda et al., 2001).
The intracellular redistribution of EBAG9 upon NGF-in-
duced differentiation in PC12 cells showed a population of
molecules that colocalized with the secretory vesicle mark-
ers synaptophysin and VAMP2 in neurites and in vesicular
structures in the vicinity of the plasma membrane. A differ-
entiation-dependent redistribution of vesicle markers also
has been reported for Synaptotagmin IV (Fukuda et al., 2003)
and hepatocyte growth factor-regulated kinase substrate
(Kwong et al., 2000). We suggest that EBAG9 is subject to a
dynamic redistribution in differentiated neuroendocrine
cells, possibly facilitated by its palmitoylation anchor. Be-
cause sorting of proteins also is regulated at the level of
protein phosphorylation (Kataoka et al., 2000; Krantz et al.,
2000), and EBAG9 was shown to be a substrate for PKA and
CKII in vitro, this effect could additionally account for the
redistribution of EBAG9 in NGF-stimulated PC12 cells.
Other phosphorylated SNARE family members that are es-
sential for distinct steps in the regulation of exocytosis in-
clude VAMP, Syntaxin, SNAP25, and SNAP23, but also the
SNARE regulatory molecules Rabphilin 3A and Synaptotag-
min (Bennett et al., 1993; Fykse et al., 1995; Nielander et al.,
1995; Cabaniols et al., 1999; Risinger and Bennett, 1999; Nagy
et al., 2004).
In conclusion, the activity of EBAG9 in regulated exocy-
tosis is mediated via its target molecule Snapin. This rela-
tionship adds not only an additional layer of control on the
exocytotic machinery but also advances our mechanistic
understanding of a process that requires a tight fine-tuning.
In view of this more physiological role, a potential function
of EBAG9 in dysregulation of exocytosis in tumor cells
requires further studies.
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